Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Spruce Biosciences, Inc. on May 22, 2024. The record date for the meeting was March 25, 2024, with 41,152,616 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document details the outcomes of two stockholder proposals:
- Proposal 1 (Election of Directors): Stockholders elected Tiba Aynechi, Ph.D., and Kirk Ways, M.D., Ph.D., as Class I Directors to serve until the 2027 Annual Meeting.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors
- Voting Results - Directors: Tiba Aynechi received 19,761,274 votes for; Kirk Ways received 19,286,428 votes for. Both had 10,667,525 broker non-votes.
- Voting Results - Auditors: The ratification of BDO USA, LLP received 30,581,608 votes for, 436,679 votes against, and 50,020 abstentions.
- Share Count: As of the record date, 41,152,616 shares were outstanding.
- Corporate Status: The company is designated as an emerging growth company.